MSCM
RPRX icon

McElhenny Sheffield Capital Management’s Royalty Pharma RPRX Stock Holding History

McElhenny Sheffield Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24
Closed -$948 – 503
2022
Q4 		$948 Buy
+24
New +$1K ﹤0.01% 572

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

McElhenny Sheffield Capital Management's RPRX Position: Q1 2023 in Review

McElhenny Sheffield Capital Management sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 24 shares — an estimated $948 sold.

McElhenny Sheffield Capital Management first reported a position in RPRX in Q4 2022 and held it in 1 quarter. The position peaked at $948 in Q4 2022. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

  • McElhenny Sheffield Capital Management reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
  • McElhenny Sheffield Capital Management sold 24 Royalty Pharma shares in Q1 2023, an estimated $948.
  • McElhenny Sheffield Capital Management first reported a position in Royalty Pharma in Q4 2022 and held it in 1 quarter.
  • McElhenny Sheffield Capital Management's Royalty Pharma position peaked at $948 in Q4 2022.
  • 335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on McElhenny Sheffield Capital Management's 13F filing for Q1 2023, filed 13 Apr 2023.